Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

Novartis

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Deferasirox

Study type: Interventional

Funder types: Industry

Identifiers

NCT00427505

CICL670A2126

Details and patient eligibility

About

This is a study to investigate the pharmacokinetics of deferasirox

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Good health
• No evidence of iron deficiency
• Weight between 50 and 100 kg
• Body Mass Index between 19 and 29 kg/m2

Exclusion criteria

• Use of certain drugs, herbal remedies or nutrients

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)